Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.33 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4047193 | 0.87 | ATR (0.36) | ATRRXRARXRBRXRGIRAK4 | |
| SCHEMBL13812030 | 0.87 | GAA (0.39) | ATRRXRARXRBRXRGIRAK4 | |
| SCHEMBL18370833 | 0.87 | ATR (0.36) | ATRRXRARXRBRXRGIRAK4 | |
| SCHEMBL5381318 | 0.84 | ATR (0.36) | ATRRXRARXRBRXRGIRAK4 | |
| SCHEMBL18370091 | 0.84 | AR (0.36) | ATRRXRARXRBRXRGIRAK4 | |
| SCHEMBL31078942 | 0.83 | MAP3K14 (0.39) | ATRRXRARXRBRXRGIRAK4 | |
| Lithium Ion SCHEMBL31078608 | 0.82 | IRAK4 (0.36) | ATRRXRARXRBRXRGIRAK4 | |
| SCHEMBL5375543 | 0.82 | ATR (0.39) | ATRRXRARXRBRXRGRET | |
| SCHEMBL5374037 | 0.81 | KDM1A (0.37) | ATRRXRARXRBRXRGIRAK4 | |
| SCHEMBL5373390 | 0.81 | CSNK1A1 (0.38) | ATRRXRARXRBRXRGCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | ATR 265/4885RXRA 2265/4885RXRB 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.